EA201201160A1 - Трициклические производные пиридина, лекарственные средства, содержащие такие соединения, их применение и способ их получения - Google Patents

Трициклические производные пиридина, лекарственные средства, содержащие такие соединения, их применение и способ их получения

Info

Publication number
EA201201160A1
EA201201160A1 EA201201160A EA201201160A EA201201160A1 EA 201201160 A1 EA201201160 A1 EA 201201160A1 EA 201201160 A EA201201160 A EA 201201160A EA 201201160 A EA201201160 A EA 201201160A EA 201201160 A1 EA201201160 A1 EA 201201160A1
Authority
EA
Eurasian Patent Office
Prior art keywords
trycyclic
connections
obtaining
application
pyridine derivatives
Prior art date
Application number
EA201201160A
Other languages
English (en)
Inventor
Хольгер Вагнер
Даниела Берта
Клаус Фукс
Риккардо Джованни
Дитер Вольфганг Хампрехт
Инго Конетцки
Рюдигер Штрайхер
Томас Тризельманн
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201201160A1 publication Critical patent/EA201201160A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

В заявке описаны соединения формулы (I)в которой переменные R-Rопределены в описании, обладающие ценной фармакологической активностью. В частности, соединения являются ингибиторами белка-переносчика сложного эфира холестерина (БПСХ) и поэтому являются подходящими для лечения и предупреждения заболеваний, на которые можно воздействовать путем ингибирования этого фермента.
EA201201160A 2010-02-19 2011-02-17 Трициклические производные пиридина, лекарственные средства, содержащие такие соединения, их применение и способ их получения EA201201160A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10154086 2010-02-19
PCT/EP2011/052376 WO2011101424A1 (en) 2010-02-19 2011-02-17 Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation

Publications (1)

Publication Number Publication Date
EA201201160A1 true EA201201160A1 (ru) 2013-04-30

Family

ID=43877277

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201201160A EA201201160A1 (ru) 2010-02-19 2011-02-17 Трициклические производные пиридина, лекарственные средства, содержащие такие соединения, их применение и способ их получения

Country Status (22)

Country Link
US (2) US9029544B2 (ru)
EP (1) EP2536733B1 (ru)
JP (1) JP5780528B2 (ru)
KR (1) KR20130000379A (ru)
CN (1) CN102869667A (ru)
AP (1) AP2012006390A0 (ru)
AR (1) AR080228A1 (ru)
AU (1) AU2011217206A1 (ru)
BR (1) BR112012020591A2 (ru)
CA (1) CA2790643A1 (ru)
CL (1) CL2012002035A1 (ru)
CO (1) CO6592112A2 (ru)
EA (1) EA201201160A1 (ru)
EC (1) ECSP12012157A (ru)
MA (1) MA34007B1 (ru)
MX (1) MX2012009149A (ru)
PE (1) PE20121743A1 (ru)
SG (1) SG183321A1 (ru)
TN (1) TN2012000418A1 (ru)
TW (1) TW201139445A (ru)
UY (1) UY33229A (ru)
WO (1) WO2011101424A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2268644B1 (en) * 2008-03-05 2011-08-17 Boehringer Ingelheim International GmbH Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
PE20121743A1 (es) 2010-02-19 2012-12-22 Boehringer Ingelheim Int Derivados de piridina triciclicos, medicamentos que contienen tales compuestos, su uso y proceso para su preparacion
EP2675811A1 (en) * 2011-02-17 2013-12-25 Boehringer Ingelheim International GmbH Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
EP2760868B1 (en) * 2011-08-17 2018-04-25 Boehringer Ingelheim International GmbH Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation
WO2013024149A1 (en) * 2011-08-18 2013-02-21 Boehringer Ingelheim International Gmbh Crystalline forms of octahydro-3h-spiro [furo [3, 4-c] quinoline -1, 4 '-pyran] -9-ol
US8633182B2 (en) 2012-05-30 2014-01-21 Boehringer Ingelheim International Gmbh Indanyloxyphenylcyclopropanecarboxylic acids
CN103866646B (zh) * 2014-03-21 2015-10-28 湖南中烟工业有限责任公司 一种生产无酮转移卡纸的工艺
CN103882766B (zh) * 2014-03-21 2015-10-28 湖南中烟工业有限责任公司 一种除去包装卡纸中酮类物质的除酮添加剂及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4798619A (en) 1980-06-02 1989-01-17 American Cyanamid Co. 2-(2-imidazolin-2-yl)-pyridines and quinolines and use of said compounds as herbicidal agents
US4475407A (en) 1982-12-27 1984-10-09 Brunswick Corporation Temperature compensated flow sensor
CH664578A5 (de) * 1985-01-15 1988-03-15 Ciba Geigy Ag Ringsubstituierte 4-azaphthalide.
EP0429464B1 (en) 1988-08-16 1994-11-23 The Upjohn Company Bivalent ligands effective for blocking acat enzyme
WO1997012870A1 (en) 1995-09-29 1997-04-10 Glaxo Wellcome S.P.A. Tetrahydroquinolines as nmda antagonists
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
JP2894445B2 (ja) 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
ID25620A (id) 1997-09-04 2000-10-19 Basf Ag Turunan-turunan asam karboksilat baru, pembuatannya dan penggunaannya sebagai campuran reseptor antagonis et a/et b
DE19741051A1 (de) 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GEP20094661B (en) 1998-09-25 2009-03-25 Pharmacia Corp (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(n+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY
US6451830B1 (en) 1999-09-23 2002-09-17 G.D. Searle & Co. Use of substituted N,N-disubstituted non-fused heterocyclo amino compounds for inhibiting cholesteryl ester transfer protein activity
US6521607B1 (en) 1999-09-23 2003-02-18 Pharmacia Corporation (R)-chiral halogenated substituted N-phenoxy N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
US20010018446A1 (en) 1999-09-23 2001-08-30 G.D. Searle & Co. Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
DE10148436A1 (de) 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
DE10238243A1 (de) * 2002-08-21 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
JP4922924B2 (ja) 2004-04-13 2012-04-25 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｅｔｐ阻害薬
PE20060653A1 (es) 2004-08-31 2006-09-27 Glaxo Group Ltd Derivados triciclicos condensados como moduladores del receptor 5-ht1
EP1828136A1 (de) 2004-12-18 2007-09-05 Bayer HealthCare AG (5s)-3-[(s)-fluor(4-trifluoromethylphenyl)methyl]-5,6,7,8-tetrahydrochinolin-5-ol derivate und ihre verwendung als cetp-inhibitoren
EP1828137B1 (de) 2004-12-18 2012-04-25 Bayer Pharma Aktiengesellschaft 4-cycloalkyl-substituierte tetrahydrochinolinderivate und deren verwendung als medikamente
DE102004060997A1 (de) * 2004-12-18 2006-06-22 Bayer Healthcare Ag Chemische Verbindung und ihre Verwendung
JP2008201760A (ja) * 2007-02-22 2008-09-04 Tokyo Univ Of Agriculture & Technology 光学活性スピロ化合物及びその製造方法
EP2268644B1 (en) 2008-03-05 2011-08-17 Boehringer Ingelheim International GmbH Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
TWI396689B (zh) 2008-11-14 2013-05-21 Amgen Inc 作為磷酸二酯酶１０抑制劑之吡衍生物
PE20121743A1 (es) 2010-02-19 2012-12-22 Boehringer Ingelheim Int Derivados de piridina triciclicos, medicamentos que contienen tales compuestos, su uso y proceso para su preparacion
EP2675811A1 (en) 2011-02-17 2013-12-25 Boehringer Ingelheim International GmbH Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
EP2760868B1 (en) 2011-08-17 2018-04-25 Boehringer Ingelheim International GmbH Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation
WO2013024149A1 (en) 2011-08-18 2013-02-21 Boehringer Ingelheim International Gmbh Crystalline forms of octahydro-3h-spiro [furo [3, 4-c] quinoline -1, 4 '-pyran] -9-ol

Also Published As

Publication number Publication date
JP2013519709A (ja) 2013-05-30
PE20121743A1 (es) 2012-12-22
AU2011217206A1 (en) 2012-08-02
CL2012002035A1 (es) 2013-02-01
AP2012006390A0 (en) 2012-08-31
CO6592112A2 (es) 2013-01-02
CA2790643A1 (en) 2011-08-25
TW201139445A (en) 2011-11-16
WO2011101424A1 (en) 2011-08-25
CN102869667A (zh) 2013-01-09
ECSP12012157A (es) 2012-10-30
TN2012000418A1 (en) 2014-01-30
EP2536733A1 (en) 2012-12-26
MX2012009149A (es) 2012-09-28
MA34007B1 (fr) 2013-02-01
US20120046304A1 (en) 2012-02-23
AR080228A1 (es) 2012-03-21
US9029544B2 (en) 2015-05-12
SG183321A1 (en) 2012-09-27
JP5780528B2 (ja) 2015-09-16
UY33229A (es) 2011-09-30
US20120053197A1 (en) 2012-03-01
KR20130000379A (ko) 2013-01-02
BR112012020591A2 (pt) 2017-10-10
EP2536733B1 (en) 2014-11-26

Similar Documents

Publication Publication Date Title
EA201201160A1 (ru) Трициклические производные пиридина, лекарственные средства, содержащие такие соединения, их применение и способ их получения
AU2018236800B2 (en) DNA-PK inhibitors
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
EA201491012A1 (ru) Гетероциклические ингибиторы глютаминазы
EA201791867A1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
EA201170963A1 (ru) Ингибиторы поли(адф-рибозо)полимеразы (parp)
WO2014031928A3 (en) Heterocyclic modulators of hif activity for treatment of disease
EA202090516A3 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
NO20093009L (no) Kondensert ring heterocykel kinase modulatorer
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
EA201491824A1 (ru) Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1
GT201400034A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
BR112016015235A2 (pt) Composto, composição farmacêutica, método de inibição da atividade da proteína quinase erk e método de tratamento
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
EA201690520A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
WO2014031933A3 (en) Heterocyclic modulators of hif activity for treatment of disease
BR112015032902A8 (pt) compostos de heteroarila, seus usos e composições farmacêuticas
MX370270B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
EA201300871A1 (ru) ПРОИЗВОДНЫЕ (1,2,4)ТРИАЗОЛО[4,3-a]ХИНОКСАЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗ
WO2014031936A3 (en) Heterocyclic modulators of hif activity for treatment of disease
CA2878796C (en) Derivatives of pyridinone as inhibitors for tissue transglutaminase
CU24052B1 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y método de producción de los mismos
MX351113B (es) Ensayo para capturar y detectar células circulantes de mieloma múltiple de la sangre.